reports
- Jean-Christophe Dourret
- Jean-Christophe Dourret
- Ron Meisels
- Valens Research
ABT - Embedded Expectations Analysis - 2018 05 15
Abbott Laboratories (ABT:USA) currently trades around recent averages relative to UAFRS-based (Uniform) Earnings, with a 22.9x Uniform P/E, implying bullish expectations for the firm. However, management has concerns about growth, Libre, and market penetration Specifically, management may lack confidence in the sustainability of double-digit sales growth in India, China, and Brazil for their Established Pharmaceuticals products, and may be exaggerating the success of the Libre launch in the U.S...
- Louis AZAIS
Medium term view - ABBOTT LABORATORIES : All-time-high
The trend has been momentarily interrupted by a correction. It approaches the support at $55.30, which also is the invalidation level. It should cause a bounce and resume the bullish trend. The next target is at $67.80. The invalidation level is below $55.30.Arguments :- The major support is close.- Prices made a new all-time-high, this confirms the strength of the trend.- The moving average is supporting prices.
- Louis AZAIS
Analyse moyen terme - ABBOTT LABORATORIES : Plus haut historique
La tendance est momentanément interrompue par une correction. Elle approche du support à 55,30 $, qui est également le niveau d'invalidation. Ceci pourrait relancer le mouvement haussier. Le prochain objectif est à 67,80 $. Le niveau d'invalidation est sous 55,30 $.Arguments :- Le support majeur est proche.- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.- La moyenne mobile sert de support.
- Louis AZAIS
- Louis AZAIS
Analyse court terme - ABBOTT LABORATORIES : Le MACD a croisé en hauss...
La tendance est toujours haussière, son niveau d'invalidation est sous 56,75 $. L'objectif est à 63,60 $.Arguments :- Le support majeur est atteint, il cause le rebond.- Le MACD a croisé en hausse.- La moyenne mobile, haussière, confirme notre avis.
- Debbie Wang
Abbott Sees Strong Start in 2018
Abbott Labs delivered strong first-quarter performance, and we expect to moderately raise our fair value estimate after adjusting our projections for key new product launches and indications, including Freestyle Libre, next-generation implantable cardioverter defibrillators, EnSite for cardiac mapping, and ongoing adoption of the Alinity system and its comprehensive test panels. The narrow-moat company is now benefiting from the rollout of internal innovation across its portfolio, as well as new...
- Louis AZAIS
Short term view - ABBOTT LABORATORIES : The support has been breached.
The trend is still bullish, though slower. The invalidation level is below $58.30.The target is at $67.50.Arguments :- The support has been breached.- The resistance has been reached, it causes the fall.- The moving average is supporting prices.
- Louis AZAIS
Analyse court terme - ABBOTT LABORATORIES : Le support est enfoncé.
La tendance est toujours haussière mais elle a ralenti. Son niveau d'invalidation est sous 58,30 $. L'objectif est à 67,50 $.Arguments :- Le support est enfoncé.- La résistance est atteinte, elle cause le repli.- La moyenne mobile sert de support.
- Valens Research
Valens Equity Insights and Inflections - 2018 03 21
EXPE currently trades near historical highs relative to UAFRS-based (Uniform) Earnings, with a 24.2x Uniform P/E. However, even at these levels, the market is pricing in expectations for Uniform ROA to continue fading from 24% in 2016 to 15% in 2021, accompanied by 16% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to fade to 15% in 2018, accompanied by 12% Uniform Asset growth. However, both market and analyst expectations appear unreasonable give...
CSX CSX CORPORATION
TXN TEXAS INSTRUMENTS INCORPORATED
PX PRAXAIR INC.
MU MICRON TECHNOLOGY INC.
GT GOODYEAR TIRE & RUBBER COMPANY
GKOS GLAUKOS CORP
EXPE EXPEDIA GROUP INC.
D DOMINION ENERGY INC
NESN NESTLE S.A.
MLM MARTIN MARIETTA MATERIALS INC.
SAN SANOFI
PKD PARKER DRILLING CO.
WMT WALMART INC.
ABT. ABBOTT LABORATORIES
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
HD THE HOME DEPOT
RCII INC.
RENT-A-CENTER INC
- Valens Research
ABT - Embedded Expectations Analysis - 2018 03 13
Abbott Laboratories (ABT:USA) currently trades near historical highs relative to UAFRS-based (Uniform) Earnings, with a 26.6x Uniform P/E, implying bullish expectations for the firm. Moreover, management is confident about cash generation and their debt targets Specifically, management is confident that their program helps EVPs be conscious of cash generation, and in their successful reorganization of St. Jude in only six months. Additionally, they are confident that they want to hit their debt...
- Louis AZAIS
Short term view - ABBOTT LABORATORIES : The moving average is supporti...
The invalidation level has barely been broken. We wait a little before taking this signal into account.Arguments :- Prices made a new all-time-high, this confirms the strength of the trend.- The moving average is supporting prices.
- Louis AZAIS
Analyse court terme - ABBOTT LABORATORIES : La moyenne mobile sert de ...
Le niveau d'invalidation a été à peine enfoncé, nous attendons un peu avant de prendre en compte ce signal.Arguments :- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.- La moyenne mobile sert de support.
Moody's upgrades Abbott Laboratories to Baa2, positive outlook
Moody's Investors Service, ("Moody's") today upgraded Abbott Laboratories ("Abbott") senior unsecured ratings to Baa2 from Baa3. Moody's also upgraded Abbott's commercial paper rating to Prime-2 from Prime-3. The rating outlook is positive. The rating upgrade reflects ...
- Louis AZAIS
Medium term view - ABBOTT LABORATORIES : All-time-high
The previous high has been passed, the bullish trend is confirmed. The next target is at $66.4000. The invalidation level is below $53.3000.Arguments :- Prices made a new all-time-high, this confirms the strength of the trend.- The ADX has peaked. The trend should be interrupted.- The moving average is supporting prices.
- Louis AZAIS
Analyse moyen terme - ABBOTT LABORATORIES : Plus haut historique
Le précédent sommet vient d'être franchi, ceci confirme la tendance haussière. Le prochain objectif est à 66,4000 $. Le niveau d'invalidation est sous 53,3000 $.Arguments :- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.- L'ADX a formé un pic. La tendance devrait s'interrompre.- La moyenne mobile sert de support.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.